The unannounced inspections were ordered in the wake of a deadly fungal meningitis outbreak linked to a Framingham pharmacy.
Outbreak victims are requesting an exhaustive inspection and testing at the facility
A federal grand jury in Boston has been seated to investigate the Framingham compounding pharmacy that manufactured tainted steroid injections blamed for at least 36 deaths.
The call for JudyAnn Bigby’s resignation follows the state drug lab scandal and the meningitis outbreak.
The group wants the FDA to revisit 16 compounding pharmacies that received warning letters from the agency between 2003 and 2012.
A federal judge is restricting some of the assets of the New England Compounding Center, but has rejected a request to freeze them completely.
Tennessee health officials will contact hundreds of people who received steroid injections for back pain from a pharmacy linked to a fungal meningitis outbreak.
State public health regulators have approved a new rule allowing hospitals to share compounded medications in the event of future drug shortages.
Lawyers for the NECC argued freezing assets would be a radical move so early after the suits were filed.
Mass. Attorney General Martha Coakley says the deadly meningitis outbreak linked to a Framingham company illustrates why a nearly 200-year-old corporate manslaughter statute should be updated.
We speak with Connecticut’s senator, following a second day of congressional hearings on the nationwide outbreak.
Dr. Lauren Smith said action should have been taken against the Framingham pharmacy at the center of the meningitis outbreak.
In her testimony in Washington, Mass. Health and Human Services Secretary JudyAnn Bigby called the outbreak “one of the greatest health care tragedies” in memory.
For a closer look at Wednesday’s meningitis outbreak hearings, and what questions remain, Harvard’s Daniel Carpenter, who specializes in regulatory law, joined WBUR.
Recently released documents show that over the past decade the state did not aggressively pursue action against the center, despite complaints.
Massachusetts lawmakers grilled Patrick administration leaders and regulators about what went wrong in the oversight of a pharmacy at the center of a meningitis outbreak.
In 2004, the company protested that a penalty could destroy its business, and in 2006, the pharmacy board agreed to impose far weaker action for reasons that remain unclear.
Hearings get underway Wednesday at the Massachusetts State House and in Washington to look into the fungal meningitis outbreak that originated at a Framingham compounding pharmacy.